Аг у взрослых. АГ у взрослых КР РФ 2019. Артериальная гипертензия у взрослых
 Скачать 0.71 Mb.
|
|
16. Мясников АЛ. Гипертоническая болезнь. М.: Медгиз, 1954. 17. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014; 13(6):4-11. 18. Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;4:4-14.do1.org/10.15829/1728-8800-2014-4-4-14. 19. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–223. 20. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 2009;119:243–250. 21. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. JHypertens 2018;36(10):1953-2041. 22. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6–31. Проект 23. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913. 24. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur Heart J Cardiovasc Pharmacother 2017;3:235–250. 25. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol 2017;74:1246–1254. 26. Rovio SP, Pahkala K, Nevalainen J, et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J Am Coll Cardiol 2017;69:2279– 2289. 27. Vishram JK, Borglykke A, Andreasen AH, et al, MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension 2012;60:1117– 1123. 28. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens 2007;20:338–341. 29. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100:354–360. 30. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J, MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002;287:2677–2683. 31. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский Кардиологический Журнал. 2018;(12):131-42. 32. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913. Проект 33. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33:44–52. 34. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet 2007; 370:1219–1229. 35. Fagard RH, Celis H, Thijs L, et al. Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51:55– 61. 36. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012; 30:449–456. 37. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47:846–853. 38. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens 2007; 25:2193– 219. 39. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35:1245–1254. 40. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685–692. 41. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012;379:905–914. 42. Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:1777–1783. 43. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self measurement of blood pressure at home: correlation with target organ damage. J Hypertens 2008;26:1919–1927. 44. Salles GF, Reboldi G, Fagard RH, et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis. Hypertension 2016;67:693–700. Проект 45. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012;30:449-56. 46. TuckerKL, SheppardJP, StevensR, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med 2017;14:e1002389. 47. Parati G, Stergiou G, O'Brien E, et al, European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014;32:1359–1366. 48. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883–891. 49. Volpe M, Battistoni A, Tocci G, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 2012;30:1056–1064. 50. Conroy, R. M., et al. "Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project." European heart journal 24.11 (2003): 987-1003. 51. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39:809–821. 52. Friedman GD, Selby JV, Quesenberry CP Jr, et al Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988;17:387– 402. 53. Дедов И.И. и соавт. "Алгоритмы специализированной медицинской помощи больным сахарным диабетом." Сахарныйдиабет 1S (2019). 54. Cosentino F., Grant P., Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2019, published online on 31 August 2019. 55. Emerging Risk Factors Collaboration. "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies." The Lancet 375.9733 (2010): 2215-2222. 56. Wilson PW, Cupples CF, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. - Amer. Heart J 1991;121:586-90. 57. Izzo R., de Simone G., Trimarco V. et al. Hypertensive target organ damage predicts incident diabetes mellitus. EurHeartJ. epub 27 June 2013. Проект 58. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612. 59. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–967. 60. Beddhu S, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002;62:1776-83. 61. Mahmoodi, Bakhtawar K., et al. "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis." The Lancet 380.9854 (2012): 1649-1661. 62. Van Der Velde, Marije, et al. "Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta analysis of high-risk population cohorts." Kidney international 79.12 (2011): 1341-1352. 63. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785– 795. 64. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3:1–150. 65. Моисеев B. C., Мухин Н. А., Смирнов А. В. и соавт. Клинические рекомендации «Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио нефропротекции» Российский кардиологический журнал 2014, 8 (112): 7–37. 66. Gerstein HC, Mann JF, Yi Q, Zinman B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426. 67. Boekholdt S. M. et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis //Jama. – 2012. – Т. 307. – №. 12. – С. 1302-1309. 68. Padwal, Raj, Sharon E. Straus, and Finlay A. McAlister. "Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review." Bmj 322.7292 (2001): 977-980. 69. Geleijnse, Johanna M., Frans J. Kok, and Diederick E. Grobbee. "Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials." Journal of human hypertension 17.7 (2003): 471. Проект 70. Macdonald, John E., and Allan D. Struthers. "What is the optimal serum potassium level in cardiovascular patients?." Journal of the American College of Cardiology 43.2 (2004): 155- 161. 71. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729–1741. 72. Grayson, Peter C., et al. "Hyperuricemia and incident hypertension: a systematic review and meta‐analysis." Arthritis care & research 63.1 (2011): 102-110. 73. Palmer, Tom M., et al. "Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts." Bmj 347 (2013): f4262. 74. Schillaci, G., Battista, F., & Pucci, G. (2012). A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. Journal of electrocardiology, 45(6), 617-623. 75. Kahn S, Frishman WH, Weissman S, et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc 1996;44:524-529. 76. Lonn E, Mathew J, Pogue J, et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prevent Rehab. 2003;10:420-428. 77. Bacharova L, Schocken D, Estes EH, Strauss D. The role of ECG in the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev 2014;10:257–261. 78. Lehtonen AO, Puukka P, Varis J, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens 2016;34:959–966. 79. Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343–2349. 80. Shashidharan, P. Comparision between Chest X Ray, Electrocardiogram and Echocardiography in Detecting Left Ventricular Hypertrophy in Essential Hypertension. 81. Verdecchia, P., Angeli, F., Borgioni, C., et al. (2003). Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension, 16(11), 895-899. |